The Effect of a Multi-modal Program on Fear of Cancer Recurrence in Breast Cancer Patients
Launched by LIU WEIMIN · Mar 16, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis meets the criteria outlined in the Breast Cancer Diagnosis and Treatment Guidelines, with a pathological diagnosis of breast cancer and currently undergoing chemotherapy
- • Age ≥ 18 years
- • Clear consciousness and the ability to communicate independently
- • Aware of the diagnosis and has signed the informed consent form
- Exclusion Criteria:
- • Presence of mental illness or cognitive impairment
- • Hearing or speech impairmen
- • Distant metastasis of cance
- • Severe physical illness or other malignant tumors requiring treatment
About Liu Weimin
Liu Weimin is a dedicated clinical trial sponsor with a focus on advancing medical research and innovation. With a commitment to enhancing patient care through rigorous scientific exploration, Liu Weimin oversees a range of clinical studies aimed at evaluating the safety and efficacy of novel therapeutic interventions. The organization emphasizes collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure compliance with ethical standards and regulatory guidelines. Through strategic partnerships and a patient-centered approach, Liu Weimin strives to contribute significantly to the development of groundbreaking therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
